QSAR study of the peptidic fibrinogen inhibitors FK633, FR158999 and related derivatives, using a novel and useful hydrophobic descriptor (logPmw).
A QSAR study using the novel hydrophobic descriptor (logPmw), which is a descriptor for membrane affinity, of our fibrinogen inhibitors FK633 (1), FR158999 (21), and related derivatives was performed, and resulted in good correlation (n = 19, s = 0.268, F = 6.38**, r = 0.667). Based on these results, we constructed a hypothesis by which these potent inhibitors bind to the receptor via the biomembrane and the C-terminal moiety functions as an anchor moiety.
Tanaka
A
A
Basic Research Laboratories, Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan.
Murata
M
M
Fujiwara
H
H
D001792:Blood Platelets / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D004151:Dipeptides / Q000737:chemistry* / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000138:chemical synthesis* / Q000737:chemistry* / Q000378:metabolism; D008567:Membranes, Artificial; D008823:Micelles; D008954:Models, Biological; D008956:Models, Chemical; D010975:Platelet Aggregation Inhibitors / Q000737:chemistry / Q000378:metabolism; D013329:Structure-Activity Relationship
D004151:Dipeptides; C116771:FR 158999; D005343:Fibrinolytic Agents; D008567:Membranes, Artificial; D008823:Micelles; D010975:Platelet Aggregation Inhibitors; C103087:((4-(4-amidinophenoxy)butanoyl)aspartyl)valine